Relative Potency of the Thrombopoietin Receptor Agonists Eltrombopag, Avatrombopag and Romiplostim in a Patient With Chronic Immune Thrombocytopenia

British Journal of Haematology- United Kingdom

doi 10.1111/bjh.15432

Full Text

Abstract

Available in

Categories

Hematology

Date

Authors

Publisher

Wiley

Related search

Thrombopoietin Level Predicts Response to Treatment With Eltrombopag and Romiplostim in Immune Thrombocytopenia

American Journal of Hematology
Hematology
2018English

Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia

Frontiers in Pediatrics
Child HealthPediatricsPerinatology
2015English

Eltrombopag, a Thrombopoietin- Receptor Agonist in the Treatment of Adult Chronic Immune Thrombocytopenia: A Review of the Efficacy and Safety Profile

Therapeutic Advances in Hematology
Hematology
2012English

The Emergence of Thrombopoietin Receptor Agonists as a Novel Treatment for Immune Thrombocytopenia

European Oncology and Haematology
OncologyHematology
2011English

Recurrent Coronary Thrombus in a Patient With Chronic Immune Thrombocytopenia With Treatment Using Eltrombopag

Case Reports in Cardiology
Cardiovascular MedicineCardiology
2019English

A United Kingdom Immune Thrombocytopenia (ITP) Forum Review of Practice: Thrombopoietin Receptor Agonists

British Journal of Haematology
Hematology
2016English

Thrombopoietin Receptor Agonists for the Treatment of Inherited Thrombocytopenia

Haematologica
Hematology
2020English

Self-Administration of Romiplostim in Patients With Chronic Immune Thrombocytopenia

Community Oncology
2013English

Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia

Clinical and Applied Thrombosis/Hemostasis
MedicineHematology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy